Replies to post #227258 on Biotech Values

[DewDiligence]

MRK—ODAC votes 9-4 in favor of Keytruda monotherapy in second-line NMIBC:

https://finance.yahoo.com/news/fda-oncologic-drugs-advisory-committee-221500044.html

This sBLA has a PDUFA date in Jan 2020; it is based on data from the single-arm KEYNOTE-057 study.